Bringing Patient Centricity To The Forefront In CAR-T Trials

Industry and regulators increasingly acknowledge that patients possess valuable expertise about their illnesses and are well-informed about treatments. Consequently, patients desire a voice in the design of investigational therapies. This concept of patient-centricity takes center stage in autologous CAR T-cell therapies, where the lines between the patient, the manufacturing process, and the product become blurred.

Throughout the administration of CAR T-cell therapies, the patient is not just the recipient but essentially becomes the product. Discover five powerful strategies for fostering patient-centricity in CAR T-cell therapy studies by downloading the infographic below and begin empowering patients today.